Reexamining treatment of high-grade T1 bladder cancer according to depth of lamina propria invasion: A prospective trial of 200 patients

British Journal of Cancer

Volumn 112, Issue 3, 2015, Pages 468-474

  Orsola, A ^a   Werner, L ^a   De Torres, I ^b   Martin Doyle, W ^c   Raventos, C X ^b   Lozano, F ^b   Mullane, S A ^a   Leow, J J ^d   Barletta, J A ^a   Bellmunt, J ^a   Morote, J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

HGT1; high risk bladder cancer; prognosis; reTUR; substaging

Indexed keywords

BCG VACCINE; MITOMYCIN;

AGED; ARTICLE; BLADDER CANCER; CANCER GROWTH; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CARCINOMA IN SITU; COHORT ANALYSIS; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LAMINA PROPRIA; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; TRANSURETHRAL RESECTION; TUMOR INVASION; TUMOR VOLUME; ADULT; CANCER GRADING; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIAL; CYSTECTOMY; MIDDLE AGED; MUCOSA; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; REOPERATION; URINARY BLADDER NEOPLASMS; URINARY TRACT; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA IN SITU; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; CYSTECTOMY; FEMALE; HUMANS; MALE; MIDDLE AGED; MUCOUS MEMBRANE; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; REOPERATION; URINARY BLADDER NEOPLASMS; URINARY TRACT;

EID: 84922227891     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.633     Document Type: Article

References (34)

1. American Urological Association (2007) Guidelines for the management of non-muscle invasive bladder cancer (stages Ta, T1, and TIS): 2007 update.
2. Aziz A, May M, Burger M, Palisaar RJ, Trinh QD, Fritsche HM, Rink M Chun F, Martini T, Bolenz C, Mayr R, Pycha A, Nuhn P, Stief C, Novotny V Wirth M, Seitz C, Noldus J, Gilfrich C, Shariat SF, Brookman-May S Bastian PJ, Denzinger S, Gierth M, Roghmann F. PROMETRICS 2011 research group (2013) Prediction of 90-day mortality after radical cystectomy for bladder cancer in a Prospective European Multicenter Cohort. Eur Urol 66(1): 156-163.
3. Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Comperat E Sylvester RJ, Kaasinen E, Bohle A, Palou Redorta J, Roupret M (2013) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 64(4): 639-653.
4. Bertz S, Denzinger S, Otto W, Wieland WF, Stoehr R, Hofstaedter F Hartmann A (2011) Substaging by estimating the size of invasive tumour can improve risk stratification in pT1 urothelial bladder cancer-evaluation of a large hospital-based single-centre series. Histopathology 59(4): 722-732.
5. Bottke D, Golz R, Storkel S, Hinke A, Siegmann A, Hertle L, Miller K Hinkelbein W, Wiegel T (2013) Phase 3 study of adjuvant radiotherapy versus wait and see in pT3 prostate cancer: impact of pathology review on analysis. Eur Urol 64(2): 193-198.
6. Chang WC, Chang YH, Pan CC (2012) Prognostic significance in substaging ofT1 urinary bladder urothelial carcinoma on transurethral resection. Am J Surg Pathol 36(3): 454-461.
7. Cheng L, Neumann RM, Weaver AL, Spotts BE, Bostwick DG (1999) Predicting cancer progression in patients with stage T1 bladder carcinoma. J Clin Oncol 17(10): 3182-3187.
8. Cottrell L, Nairn ER, Hair M (2007) Consistency of microstaging pT1 bladder transitional cell carcinoma. J Clin Pathol 60(6): 735-736.
9. Denzinger S, Otto W, Fritsche HM, Roessler W, Wieland WF, Hartmann A Burger M (2007) Bladder sparing approach for initial T1G3 bladder cancer: Do multifocality, size of tumor or concomitant carcinoma in situ matter? A long-term analysis of 132 patients. Int J Urol 14(11): 995-999 discussion 999.
10. Descotes F, Dessen P, Bringuier PP, Decaussin M, Martin PM, Adams M Villers A, Lechevallier E, Rebillard X, Rodriguez-Lafrasse C, Devonec M Paparel P, Perrin P, Lazar V, Ruffion A (2013) Microarray gene expression profiling and analysis of bladder cancer supports the sub classification of the T1 tumours in T1a and T1b stages. BJU Int 113(2): 333-342.
11. Divrik RT, Sahin AF, Yildirim U, Altok M, Zorlu F (2010) Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence progression rate, and disease-specific survival: a prospective randomised clinical trial. Eur Urol 58(2): 185-190.
12. Eble JN, Sauter G, Epstein JI, Sesterhenn IA (2006) World Health Organization Classification of Tumors. Tumors of the Urinary System and Genital Organs. IARC Press: Lyon.
13. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW Comber H, Forman D, Bray F (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49(6): 1374-1403.
14. Gontero P, Sylvester R, Pisano F, Joniau S, Vander Eeckt K, Serretta V Larre S, Di Stasi S, Van Rhijn B, Witjes AJ, Grotenhuis AJ, Kiemeney LA Colombo R, Briganti A, Babjuk M, Malmstrom PU, Oderda M, Irani J Malats N, Baniel J, Mano R, Cai T, Cha EK, Ardelt P, Varkarakis J Bartoletti R, Spahn M, Johansson R, Frea B, Soukup V, Xylinas E Dalbagni G, Karnes RJ, Shariat SF, Palou J (2014) Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guerin: results of a retrospective multicenter study of 2451 patients. Eur Urol 67(1): 74-82.
15. Herr HW, Donat SM, Dalbagni G (2007) Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy? J Urol 177(1): 75-79, discussion 79.
16. Jakse G, Algaba F, Malmstrom P, Oosterlinck W (2004) A second-look TUR in T1 transitional cell carcinoma: why? Eur Urol 45(5): 539-546 discussion 546.
17. Kiemeney LA, Witjes JA, Heijbroek RP, Koper NP, Verbeek AL, Debruyne FM (1994) Should random urothelial biopsies be taken from patients with primary superficial bladder cancer? A decision analysis. Members of the Dutch South-East Co-Operative Urological Group. Br J Urol 73(2): 164-171.
18. Martin-Doyle W, Leow J, Orsola A, Cheng S, Bellmunt J (2014) Improving selection criteria for early cystectomy in high-grade T1 bladder cancer: A meta-analysis of 15,215 patients. J Clin Oncol (under edition).
19. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J Vicente-Rodriguez J (2000) Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 163(1): 73-78.
20. Orsola A, Cecchini L, Raventos CX, Trilla E, Planas J, Landolfi S, de Torres I Morote J (2010) Risk factors for positive findings in patients with highgrade T1 bladder cancer treated with transurethral resection of bladder tumour (TUR) and bacille Calmette-Guerin therapy and the decision for a repeat TUR. BJU Int 105(2): 202-207.
21. Orsola A, Trias I, Raventos C, Espanol I, Cecchini L, Bucar S, Salinas D Orsola I (2005) Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients. Eur Urol 48(2): 231-238, discussion 238.
22. Palou J, Sylvester RJ, Faba OR, Parada R, Pena JA, Algaba F, Villavicencio H (2012) Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guerin. Eur Urol 62(1): 118-125.
23. Pansadoro V, Emiliozzi P, de Paula F, Scarpone P, Pansadoro A, Sternberg CN (2002) Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guerin: 18-year experience. Urology 59(2): 227-231.
24. Raj GV, Herr H, Serio AM, Donat SM, Bochner BH, Vickers AJ, Dalbagni G (2007) Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. J Urol 177(4): 1283-1286 discussion 1286.
25. Roupret M, Seisen T, Comperat E, Larre S, Mazerolles C, Gobet F, Fetissof F Fromont G, Safsaf A, dArcier BF, Celhay O, Validire P, Rozet F, Irani J Soulie M, Pfister C. Comite de Cancerologie de lAssociation Francaise dUrologie (2013) Prognostic interest in discriminating muscularis mucosa invasion (T1a vs T1b) in nonmuscle invasive bladder carcinoma: French National Multicenter Study with central pathology review. J Urol 189(6): 2069-2076.
26. Sfakianos JP, Kim PH, Hakimi AA, Herr HW (2014) The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Guerin. J Urol 191(2): 341-345.
27. Skolarus TA, Ye Z, Montgomery JS, Weizer AZ, Hafez KS, Lee CT, Miller DC Wood DP, Montie JE, Hollenbeck BK (2011) Use of restaging bladder tumor resection for bladder cancer among Medicare beneficiaries. Urology 78(6): 1345-1349.
28. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C Denis L, Newling DW, Kurth K (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49(3): 466-465, discussion 475-477.
29. van den Bosch S, Alfred Witjes J (2011) Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review. Eur Urol 60(3): 493-500.
30. van der Aa MN, van Leenders GJ, Steyerberg EW, van Rhijn BW, Jobsis AC Zwarthoff EC, van der Kwast TH (2005) A new system for substaging pT1 papillary bladder cancer: a prognostic evaluation. Hum Pathol 36(9): 981-986.
31. van Rhijn BW, Liu L, Vis AN, Bostrom PJ, Zuiverloon TC, Fleshner NE van der Aa MN, Alkhateeb SS, Bangma CH, Jewett MA, Zwarthoff EC Bapat B, van der Kwast TH, Zlotta AR (2012) Prognostic value of molecular markers, sub-stage and European Organisation for the research and treatment of cancer risk scores in primary T1 bladder cancer. BJU Int 110(8): 1169-1176.
32. van Rhijn BW, van der Kwast TH, Alkhateeb SS, Fleshner NE, van Leenders GJ Bostrom PJ, van der Aa MN, Kakiashvili DM, Bangma CH, Jewett MA Zlotta AR (2012) A new and highly prognostic system to discern T1 bladder cancer substage. Eur Urol 61(2): 378-384.
33. Witjes JA, Babjuk M, Gontero P, Jacqmin D, Karl A, Kruck S Mariappan P, Palou Redorta J, Stenzl A, van Velthoven R, Zaak D (2014) Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations. Eur Urol; e-pub ahead of print 4 July 2014; doi:10.1016/j.eururo.2014.06.037.
34. Xylinas E, Kent M, Kluth L, Pycha A, Comploj E, Svatek RS, Lotan Y Trinh QD, Karakiewicz PI, Holmang S, Scherr DS, Zerbib M, Vickers AJ Shariat SF (2013) Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder. Br J Cancer 109(6): 1460-1466.